Answers are grounded in this paper and cite their sources.
Molecular techniques are the gold standard method for the diagnosis of AML with mutated nucleophosmin gene ( NPM1 mut ). However, their worldwide availability is limited and they provide limited insight into disease heterogeneity. Hence, surrogate markers of NPM1 mut are used for fast diagnostic screening of the disease [ 1 ], including, among others, immunohistochemical detection of cytoplasmic NPM1 (NPM1c) [ 2 ], cup-like nuclear morphology [ 3 ], normal karyotype, and/or recurrent flow cytometry profiles -e.g., CD34 negativity, and/or a phenotype resembling acute promyelocytic leukemia (APL)- [ 4 ]. Nevertheless, some of these methods are also not widely available, they show limited sensitivity (e.g., low or absent NPM1c expression, particularly among monoblastic/monocytic AML- NPM1 mut ) [ 5 ], frequently lack standardized procedures [ 1 ], and they might also bring limited information about disease heterogeneity.
No takes yet. Share an insight, caveat, or question.
Matarraz et al. (2023) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: